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Niemann-Pick C1-like 1 (NPC1L1) is an intestinal cholesterol transporter and the molecular target of ezetimibe, a cholesterol absorption
inhibitor demonstrated to reduce LDL-cholesterol (LDL-C) both as monotherapy and when co-administered with 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statins). Interestingly, significant interindividual variability has been observed for rates of intestinal cholesterol
absorption and LDL-C reductions at both baseline and post ezetimibe treatment. To test the hypothesis that genetic variation in NPC1L1 could
influence the LDL-C response to ezetimibe, we performed extensive resequencing of the gene in 375 apparently healthy individuals and
genotyped hypercholesterolemic patients from clinical trial cohorts. No association was observed between NPC1L1 single-nucleotide
polymorphism and baseline cholesterol. However, significant associations to LDL-C response to treatment with ezetimibe were observed in
patients treated with ezetimibe in two large clinical trials. Our data demonstrate that DNA sequence variants in NPC1L1 are associated with an
improvement in response to ezetimibe pharmacotherapy and suggest that detailed analysis of genetic variability in clinical trial cohorts can lead to
improved understanding of factors contributing to variable drug response.
D 2005 Elsevier Inc. All rights reserved.Keywords: Target of ezetimibe; NPC1L1; Drug response; Genetic association; Clinical trial; CholesterolIntroduction
Niemann-Pick C1-like 1 (NPC1L1) is an intestinal choles-
terol transporter and the molecular target of ezetimibe ([1,2]), a0888-7543/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygeno.2005.08.007
i The NPC1L1 SNP data can be found at www.pharmgkb.org using the
PharmGKB Accession ID PS205315.
* Corresponding authors. J.S. Simon is to be contacted at Discovery
Technologies, Schering-Plough Research Institute, 2015 Galloping Hill Road,
Kenilworth, NJ 07090, USA. Fax: +1 (908) 740 7101. E.E. Schadt, Department
of Research Genetics, Rosetta Inpharmatics, LLC, 401 Terry Avenue N.,
Seattle, WA 98109, USA.
E-mail addresses: jason.simon@spcorp.com (J.S. Simon),
eric_schadt@merck.com (E.E. Schadt).
1 Present address: Amgen Inc., One Amgen Center Drive, Bldg. 38-3A
Thousand Oaks, CA 91360, USA.
2 A wholly owned subsidiary of Merck & Co., Inc.cholesterol absorption inhibitor demonstrated to reduce LDL-
cholesterol (LDL-C) both as monotherapy ([3–5]) and when
co-administered with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) [6,7]. Interestingly, significant
interindividual variability has been observed for rates of
intestinal cholesterol absorption and LDL-C reductions at both
baseline and post ezetimibe treatment [8].
Several lines of evidence link NPC1L1 to the uptake of
dietary cholesterol including high-level expression in the
primary site of cholesterol absorption, the jejunum of the small
intestine, as well as the observation that NPC1L1 knockout
(NPC1L1/) mice have ¨70% lower cholesterol absorption
than wildtype [1]. These mice do not respond to ezetimibe with
additional lowering of cholesterol absorption [1]. Ezetimibe
binds to a single site in jejunum brush border membranes
from wildtype but not NPC1L1/ mice, as well as human5) 648 – 656
www.el
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tions support the role of NPC1L1 in intestinal cholesterol ab-
sorption and as the target of ezetimibe. To explore how naturally
occurring variation in NPC1L1 may affect LDL-C response to
ezetimibe added to ongoing statin therapy, we extensively
characterized DNA sequence variability in this gene in a set of
375 anonymous individuals and subsequently performed anal-
ysis to determine whether common DNA sequence variants
associated with clinical response to ezetimibe added on or given
in combination with statin in two large clinical trial cohorts.
Results
To test the hypothesis that genetic variation in NPC1L1
could influence the LDL-C response to ezetimibe, we
performed extensive resequencing of the gene in 375 appar-
ently healthy individuals (n = 198 Caucasians, n = 99 African
Americans, and n = 78 Hispanics) and genotyped hypercho-
lesterolemic patients from a clinical trial cohort. No association
was observed between NPC1L1 single-nucleotide polymorph-
isms (SNPs) and baseline cholesterol. Tagging SNPs were
identified for primary analyses. Significant associations were
observed in patients in the Ezetimibe Add-on to Statin for
Effectiveness (EASE) Trial [9] among a tagging SNP, SNP
(g.-18C > A; P = 0.0043, n = 1195), and 3-tagging SNP
haplotype (A-A-G (g.-133A > G/g.-18C > A/g.1679C >
G:L272L); P = 0.0046) in the NPC1L1 gene and response to
ezetimibe added onto existing statin therapy. The association
with NPC1L1 was replicated in a second clinical trial cohort
(g.-133A > G p = 0.0173, g.1679C > G(L272L) P = 0.0116 n =
556, A-A-G P = 0.0081). Patients carrying at least one minor
allele at g.-18C > A demonstrated a 15% improved reduction in
LDL-C on average compared to homozygote wildtype patients.
The 5V promoter SNP and 3-SNP haplotype was also
significantly associated with the percentage change in the
plant sterol sitosterol (g.-18C > A, P = 0.0200, n = 832; A-A-
G, P = 0.0203) measured in EASE patients in the ezetimibe +
statin arm, suggesting an effect on inhibition of absorption of
both dietary and synthesized derived sterol. These data
demonstrate that DNA sequence variants in NPC1L1 are
associated with an improvement in response to ezetimibe
pharmacotherapy and suggest that detailed analysis of genetic
variability in clinical trial cohorts can lead to improved
understanding of factors contributing to variable drug response.
In total, 140 SNPs and five insertions/deletions were
identified (Supplementary Fig. 1a and Supplementary Table
1). Thirty-four polymorphisms localized to the NPC1L1 coding
sequence, 20 of which are missense mutations. Table 1
highlights the 24 SNPs with minor allele frequencies (MAFs)
>4% in at least one ethnic group from the resequencing cohort.
The resequenced region of NPC1L1 encompassed 20,094
bases, so that the average number of SNPs per kilobase was
0.083725 for common SNPs and 6.96725 for all SNPs,
consistent with ratios reported over broader sets of genes
[10]. The LD structure for NPC1L1 was assessed and
visualized using standard DV and R2 measures as implemented
in the Haploview program (Supplementary Fig. 1b) using theFour Gamete Rule with a minimum threshold of 0.05 [10,11].
Generally weak DV values were observed despite a sample
size of n = 375 individuals. Interestingly, this gene had a
recombination hotspot intensity of 45, computed using the
Phase v2.0 software package [9], as previously described [12].
This suggests that NPC1L1 has a significantly increased rate of
recombination compared to other genes.
We successfully converted 13 SNPs to valid TaqMan
genotyping assays, including all SNPs with MAF >4% in all
the ethnic groups of the resequencing cohort. These SNPs were
genotyped in 1208 individuals participating in the ezetimibe +
statin treatment arm of the EASE trial ([13]) (see Materials and
Methods and Supplementary Table 2). Twelve of 13 SNPs
genotyped in the EASE cohort were confirmed as common in
all ethnicities. Furthermore, allele frequencies for 5 SNPs in the
African American ethnic group of the EASE cohort were
significantly different from the corresponding frequencies in
the resequencing cohort, potentially indicating different popu-
lation substructures between these two groups in this gene. In
addition, the minor allele frequency for SNP g.28650A > G in
the Caucasian resequencing cohort (4.9%) differed significant-
ly from the frequency in the EASE cohort (21% in Caucasians,
P = 6.7  1014), suggesting that this SNP may be
significantly associated with baseline LDL-C levels, given that
the EASE cohort is hypercholesterolemic, whereas the rese-
quencing cohort is expected to represent a random population
sample with respect to cholesterol levels.
The LD structure through the NPC1L1 gene was more
apparent with the large number of individuals genotyped in the
EASE cohort (Supplementary Fig. 1b). Haplotypes calculated
using 12 SNPs genotyped in the EASE cohort withMAF4% in
all ethnicities were inferred using the PHASE v2.0 software
package at the default settings [9]. Haplotypes for all chromo-
somes observed were then clustered by similarity using an
agglomerative hierarchical clustering procedure. SNPswere also
clustered by allelic similarity using the same type of clustering
procedure (Supplementary Fig. 2). We visually identified 6
tagging SNPs that represent eight commonNPC1L1 haplotypes.
These eight haplotypes explain >80% of the haplotype diversity
in the EASE cohort. A general linear model was then used to
assess whether the LDL-C response predictive baseline variables
in the EASE cohort were significantly associated with any of the
NPC1L1 tagging SNPs. We found no significant associations
between response predictive variables (including baseline LDL-
C levels) and any of the SNPs. The six tagging SNPs were then
used to characterize genetic association between NPC1L1 and
LDL-C response to treatment with ezetimibe added to 6weeks of
stable dose ongoing statin (any dose, any brand) therapy.
Subjects in the ezetimibe + statin group had a significantly
greater reduction in LDL-C than placebo + statin subjects
(25.8% vs. 2.7%, P < 0.001) ([13]).
Table 2 summarizes the association results for the six
tagging SNPs. SNP g.-18C > A, located 18 nucleotides
upstream of the initiating ATG of NPC1L1, was found to be
significantly associated with LDL-C response to ezetimibe
treatment in the EASE cohort (P value = 0.0043). Patients
homozygous for the common allele of g.-18C > A (n = 875/
Table 1
Summary of alleles and associated frequencies for SNPs identified in the NPC1L1 gene from the dbSNP database and from resequencing a cohort of 375 ethnically
diverse individuals
SNP Source Resequencing EASE cohort
Caucasian
(N = 198)
Hispanic
(N = 78)
African American
(N= 99)
Caucasian
(N = 1003)
Hispanic
(N = 52)
Asian
(N = 39)
African American
(N = 101)
g.-982G > C Reseq 3.1 0.6 5.1 NG NG NG NG
g.-762T > Ca Reseq/rs2073548 0.3 8.3 3.1 NG NG NG NG
g.-133A > Ga,b Reseq 29.9 18.6 9.2 30.0 23.0 6.0 8.0
g.-18C > Aa,b Reseq 18.1 7.5 6.0 16.0 5.0 5.0 5.0
g.1679C > G (L272L) Reseq/rs2072183 21.9 28.3 17.9 22.0 22.0 35.0 20.0
g.1680G > Ta Reseq 0.0 7.9 0.0 NG NG NG NG
g.1791G > Ta Reseq 0.0 0.0 4.0 NG NG NG NG
g.2023A > G (N387S)a,b Reseq 0.0 0.0 5.1 0.001 0.0 0.0 12.0
g.3237C > Tb Reseq 13.2 7.7 8.4 17.0 6.0 4.0c 8.0
g.6893C > Ta Reseq 0.0 0.0 11.2 NG NG NG NG
g.9096T > Ga Reseq 0.0 0.6 5.0 NG NG NG NG
g.9202C > Ta,b Reseq 14.3 8.9 5.6 17.0 5.0 3.0 7.0
g.9231G > A Reseq 4.6 3.8 6.6 NG NG NG NG
g.16124A > Ga,b Reseq/rs1088837 24.5 8.3 10.4 25.0 19.0 6.0 22.0d
g.18958T > Ga,b Reseq 23.7c 8.4 16.8 24.0 16.0 5.0 29.0d
g.18975G > A Reseq/rs4720470 4.9 10.4 4.6 NG NG NG NG
g.19224G > Ab Reseq 10.6 8.6 3.8 8.0 5.0 100.0 3.0
g.19259T > Ca,b Reseq 23.1 1.9 15.2 25.0 18.0d 4.0 30.0d
g.23825G > Aa Reseq 0.3 0.0 4.2 NG NG NG NG
g.25286A > Ca Reseq/rs1315929 24.2c 30.5 8.0 NG NG NG NG
g.25435C > T (Y1264Y) Reseq 19.7 19.2 29.2 NG NG NG NG
g.27621T > C (V1269V)b Reseq 19.5 17.1 13.0 23.0 12.0 4.0 7.0
g.28650A > Gb Reseq 4.9 3.8 3.5 21.0d 17.0d 4.0 15.0c,d
g.28763DELb Reseq 18.1 8.7 13.8 21.0 13.0 4.0 5.0d
Note. Frequencies for the minor allele are given for the resequencing and EASE cohorts described in the text. Indications are given if allele frequencies for any SNP
in either cohort violated Hardy-Weinberg equilibrium, were significantly different between the cohorts, or were significantly different between any two of the races
within a given cohort. NS indicates that the SNP occurred in a region of the gene (e.g., intron) that was not sequenced, and NG indicates SNPs that were not
genotyped in the EASE cohort.
a Statistically significant differences in allele frequencies between at least two ethnicities in the resequencing cohort ( P < 0.005).
b Statistically significant differences in allele frequencies between at least two ethnicities in the EASE cohort ( P < 0.005).
c Statistically significant departure from Hardy-Weinberg Equilibrium ( P < 0.01 using the Exact Test for HWE).
d Statistically significant differences in allele frequencies between the resequencing and EASE cohorts in at least one ethnic group ( P < 0.005).
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baseline compared to 27.8% for patients heterozygous for the
minor allele (298/1195; 25.0%), a 15% increased response
(Supplementary Fig. 3). Individuals homozygous for the minor
allele (n = 22/1195; 1.8%) had a mean change in LDL-C of
27.3%, not significantly different from the heterozygotes.
Because Caucasians were the dominant ethnicity represented
in the EASE cohort (1003/1195 individuals; 83.9%), we
repeated this analysis using only these subjects. The associa-
tion between LDL-C response and g.-18C > A in the
Caucasian-only subset of EASE was again found to be
statistically significant (Table 2).
To further explore the association between g.-18C > A and
response to ezetimibe treatment, we examined individuals in
the EASE cohort that fell in the tails of the response
distribution, defined as the upper and lower 10th percentiles
of LDL-C responders to ezetimibe added onto statin therapy
(Supplementary Table 4). Association between g.-18C > A and
LDL-C response was also found to be significant in the
extreme responder subgroup (P = 0.0005 for the general
association categorical test). Patients homozygous for the
common allele in the extreme responders (176/239 individuals;
73.6%) had a mean LDL-C percentage change of 16.8%,whereas the heterozygotes had a mean LDL-C percentage
change of 33.98%, a 100% increase in efficacy (Supplemen-
tary Fig. 4). In addition to g.-18C > A, one additional SNP
(g.1679C > G) was significantly associated with LDL-C
response in this extreme responder analysis. Given the
significant association of SNP g.-18C > A to LDL-C response
and the two SNPs flanking this SNP in LD block 1 shown in
Supplementary Fig. 2, we examined all three SNP haplotypes
(Table 3) for association to LDL-C response in the extreme
responders defined above. Carriers of the A-A-G haplotype
containing the minor allele of the SNP g.-18C > A had
significantly improved LDL-C response compared to non-
carriers (P = 0.0008). This pattern was also apparent in the
analysis of the diplotypes (data not shown). No individual
haplotype associations were found to be more significantly
associated with response than SNP g.-18C > A. Furthermore,
none of the seven nontagging SNPs that were genotyped in the
EASE cohort were found to be as significantly associated with
LDL-C response as SNP g.-18C > A. In addition, none of the
eight most common haplotypes identified in the EASE cohort
were found to be as significantly associated with LDL-C
response as SNP g.-18C > A and the A-A-G haplotype.
Importantly, SNP g.-18C > A and the A-A-G haplotype
Table 2
Tagging SNPs tested for association with LDL-C response to EZE treatment
SNP SNP
P value
Least-squares adjusted mean
(n/SE)
High-responder vs. low-responder association with SNP (Percentage change in LDL-C
either less than the 10th or greater than the 90th percentile)
N = 239 general
association test P value
SNP P value Least-squares adjusted)
mean (n/SE)
g.-133A > G 0.142 A/A 25.92 (629/0.68) 0.072 0.093
A/G 24.58 (477/0.78)
G/G 22.56 (89/1.80)
g.-18C > Aa 0.0043 A/A 27.27 (22/3.61) 0.0005 0.0003 A/A n = 0
(0.026) C/A 27.85 (298/0.98) (0.003) (0.0018) C/A 33.98 (62/4.05)
C/C 24.16 (875/0.57) C/C 16.85 (177/2.40)
Odds ratioa = 2.94 ;
CI = (1.59, 5.44)
g.1679C > G (L272L) 0.129 C/C 24.50 (723/0.63) 0.012 (0.072) 0.028 (0.170) C/C 17.49 (143/2.71)
C/G 25.77 (417/0.83) C/G 25.16 (85/3.51)
G/G 28.77 (55/2.29) G/G 40.93 (11/9.76)
g.19224G > A 0.643 A/A 31.64 (/6.94) 0.597 0.710
G/A 25.07 (/1.34)
G/G 25.11 (/0.53)
g.19259T > C 0.807 C/C 26.38 (/1.98) 0.846 0.598
T/C 25.01 (/0.82)
T/T 25.07 (/0.64)
g.28650A > G 0.108 A/A 24.40 (/0.60) 0.101 0.079
A/G 26.50 (/0.89)
G/G 27.19 (/2.65)
Note. If a significant P value was achieved for association between response and SNP genotype (at the 0.01 level), the Bonferroni-corrected P value (for six SNPs in
the primary analysis) is given in parentheses. Columns 4 through 6 provide test results in the extreme responders of the treated arm of the EASE cohort, as described
in the text.
a Given the response counts; CI denotes 95% confidence interval.
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adjusting for baseline LDL-C levels. Note that baseline LDL-C
levels were not significantly associated with SNP G.-18C > A
or any of the other five tagging SNPs tested.
To validate the associations detected in the EASE cohort, we
genotyped the g.-133A > G, g.-18C > A, and g.1679C > G
SNPs in the Vytorin vs. Atorvastatin (VYVA) clinical trialTable 3
Association test results for the fivemost common 3-SNP haplotypes constructed from S
3-SNP haplotypes P valuea Number
g.-133A > G
g.-18C > A
g.1679C > G
of copies
A-A-C 0.280 0
1
A-A-G 0.0005 0
1
A-C-C 0.225 0
1
2
A-C-G 0.115 0
1
2
G-C-C 0.062 0
1
2
Note. A haplotype trend test was used to determine whether individuals carrying
response. The third column represents the coding used for classifying individuals
categorical variables in the generalized linear model. P value for the F test where nul
two copies of the haplotype are observed.
a Model including all haplotypes.
b Model including only corresponding hapotype.population (Materials and Methods). In this replication cohort,
SNP g.1679C > G was found to be significantly associated
(P = 0.012) with the percentage change in LDL-C, validating
the significant association identified in the EASE cohort (Table
4). SNP g.-18C > A was not found to be significantly
associated with LDL-C reduction in response to treatment
with ezetimibe/simvastatin combination therapy. However,NPs g.-133A>G, g.-18C >A, and g.1678C>G tested in the extreme responders
Counts Adjusted least-squares P valueb
Mean (SE)
235
4
181 17.32 (2.38) 0.0008
58 33.69 (4.21)
45
129
65
197
36
6
139 24.51 (2.75) 0.0342
92 18.62 (3.38)
8 3.93 (11.45)
different numbers of a given haplotype differed significantly with respect to
as carrying zero, one, or two copies of the haplotype. Counts were treated as
l hypothesis is mean response does not differ significantly whether zero, one, or
Table 4
Tagging SNPs tested for association with LDL-C response to ezetimibe treatment in the EASE trial and in the VYVA trial
Marker Caucasians in EASE trial Caucasians on ezetimibe in VYVA triala
Number of
individuals
Minor
allele
Frequency Baseline
P value
SNP
P value
Linear model least-squares Number of
individuals
Minor
allele
Frequency Baseline
P value
SNP
P value
Linear model least-squares
Mean SE Mean SE
g.-133A > G 1003 G 0.30 <0.0001 0.0205 A/A 26.65 0.71 556 G 0.28 0.0608 0.0173 A/A 55.71 0.83
A/G 24.89 0.74 A/G 54.59 0.83
G/G 21.99 1.66 G/G 47.22 2.88
g.-18C > Aa 1003 A 0.16 <0.0001 0.002 A/A 26.28 3.37 556 A 0.17 0.0623 0.4550 A/A 57.26 3.21
C/A 28.22 0.92 C/A 55.65 1.08
C/C 24.36 0.58 C/C 54.38 0.70
g.1679C > G
(L272L)
1003 G 0.22 <0.0001 0.0872 C/C 24.61 0.63 556 G 0.23 0.0606 0.0116 C/C 53.42 0.75
C/G 26.80 0.82 C/G 56.48 0.94
G/G 27.01 2.42 G/G 58.77 2.55
g.28650A > G 1002 G 0.21 <0.0001 0.0442 A/A 24.53 0.62 556 G 0.22 0.0626 0.7443 A/A 54.48 0.74
A/G 26.97 0.84 A/G 55.43 0.98
G/G 27.64 2.48 G/G 54.95 2.57
Note. Columns are similar to those reported for Table 2.
a LDL-C response values were adjusted by treatment group in the VYVA trial to remove any effects that may be attributed to simvastatin dose. No interaction between SNP and dose of simvastatin in the VYVA trial
was detected, so that the SNPs are predictive of response to ezetimibe when combined with any the simvastatin doses studied.
Table 5
3-SNP haplotypes tested for association to LDL-C response to treatment with ezetimibe
Caucasians in EASE trial Caucasians in VYVA trial
3-SNP haplotypes Count Percentage Baseline Haplotype Linear model least-squares 3-SNP haplotypes Count Percentage Baseline Haplotype Linear model least-squares
g.-133A > G
g.-18C > A
g.1679C > G
P value P value
Mean SE g.-133A > G
g.-18C > A
g.1679C > G
P value P value
Mean SE
A-A-G 308 15.35 <0.0001 0.0046 A-A-G 27.76 0.88 A-A-G 177 15.92 0.0034 0.0081 A-A-G 56.16 1.02
A-C-C 948 47.26 A-C-C 25.67 0.50 A-C-C 520 46.76 A-C-C 54.53 0.59
A-C-G 127 6.33 A-C-G 24.34 1.37 A-C-G 86 7.73 A-C-G 58.76 1.46
G-C-C 608 30.31 G-C-C 23.99 0.63 G-C-C 311 27.97 G-C-C 58.58 0.77
Both studies combined
3-SNP haplotypes Count Percentage Baseline Haplotype Linear model least-squares
g.-133A > G
g.-18C > A
g.1679C > G
P value P value
Mean SE
A-A-G 485 15.72 <0.0001 0.0011 A-A-G 41.47 0.68
A-C-C 1468 47.59 A-C-C 39.49 0.40
A-C-G 213 6.90 A-C-G 40.38 1.03
G-C-C 919 29.79 G-C-C 38.20 0.50
Note. The haplotypes comprise the same three SNPs described in Table 3. The association tests are carried out in Caucasians in the EASE trial, the VYVA trial, and in the two trials combined.
J.S
.
S
im
o
n
et
a
l.
/
G
en
o
m
ics
8
6
(2
0
0
5
)
6
4
8
–
6
5
6
6
5
2
J.S. Simon et al. / Genomics 86 (2005) 648–656 653replication was achieved in the second cohort at the haplotype
level. In considering the three SNP haplotypes, significant
associations to LDL-C response are detected in the EASE (P =
0.0046) and VYVA (P = 0.0081) trials (Table 5). We further
note that these three SNPs were also genotyped in the statin-
only arms of the EASE and VYVA cohorts. Neither of these
SNPs showed an association with the LDL-C response to statin
treatment in these arms. In addition, there were no associations
between LDL-C response predictive variables (including
baseline LDL-C levels) and any of the SNPs, including all
SNPs typed in the EASE cohort.
Given the role of NPC1L1 in sterol absorption, it is likely
that the effect of genetic variation is on intestinal transporter
activity. Therefore, to test whether NPC1L1 sequence variants
affected sterol transport (as opposed to cholesterol homeostatic
mechanisms more generally), we assessed the effect of
individual SNPs and the 3-SNP haplotype on changes in
plasma sitosterol levels in Caucasian EASE patients pre- and
postaddition of ezetimibe to ongoing statin therapy. Sitosterol,
a noncholesterol plant sterol, is a substrate for the NPC1L1
transporter and a direct marker of cholesterol absorption
([14,15]). Significant associations (Table 6) were observed
between SNP g.-18C > A (P = 0.0200, n = 832) and the
previously associated 3-SNP haplotype (P = 0.0203). No
association was observed between these SNPs and baseline
sitosterol levels. In addition, no association was observed
between plasma lathosterol, a marker of cholesterol biosynthe-
sis [16], and NPC1L1 SNPs at baseline or with the change
post-treatment with ezetimibe + statin. These data strongly
support the hypothesis that variability in NPC1L1 affects
intestinal sterol absorption rather than cholesterol biosynthesis.
Future kinetic studies directly evaluating sterol absorption will
be necessary for confirmation.
Based on the functional role of NPC1L1 in cholesterol
absorption and the observed association of common variants in
NPC1L1 with change in LDL-C in the present study, it wouldTable 6
SNP and 3-SNP haplotype tested for association with response to the percentage cha
clinical trial cohort
Caucasians in EASE trial
SNP Baseline sitosterol SNP Genotype
P value P value
g.-133A > G <0.0001 0.2973
g.-18C > A <0.0001 0.0200 A/A
C/A
C/C
g.1678C > G <0.0001 0.1264
3-SNP haplotypes Count Percentage Baseline sit
g.-133A > G
g.-18C > A
g.1679C > G
P value
A-A-G 251 15.32 <0.0001
A-C-C 776 47.37
A-C-G 105 6.41
G-C-C 506 30.89
Note. The haplotypes comprise the same three SNPs described in Table 3.appear to be possible that variability in baseline LDL-C could
also be explained by DNA sequence variability in NPC1L1.
However, no variants in this study were associated with
baseline LDL-C. It should be noted, however, that patients in
these two cohorts were hypercholesterolemic, reducing the
power to detect baseline associations. There was, however, an
unexpected overrepresentation of an NPC1L1 3V UTR SNP in
the EASE population compared to the population control
resequencing group. A striking threefold increase in the
frequency of g.28650A > G was found in the EASE versus
resequencing cohorts. One plausible explanation is that this
SNP predicts risk for elevated LDL-C. An alternative is that
g.28650A > G predicts poor response to statins by evidence of
its high level of representation in patients on statin mono-
therapy not at NCEP Adult Treatment Panel (ATPIII) recom-
mended cholesterol levels. No association was found between
baseline LDL-C levels and this SNP in the EASE population,
but this analysis is confounded by statin treatment and the lack
of prestatin LDL-C levels Follow-up in a population-based
case control study evaluating association of g.28650A > G with
baseline LDL-C levels in an untreated cohort could confirm
such an association.
It is unlikely that the SNPs found associated with LDL-C
response in this study represent the causal variants, given that
no single SNP was found to support the full magnitude of the
effect associated with the 3-SNP haplotype in both clinical trial
cohorts. In addition, there were several 2-SNP haplotypes
identified in the combined EASE and VYVA cohorts that were
more significantly associated with LDL-C response than the 3-
SNP haplotypes. For example, carriers of the A-A haplotype
corresponding to the SNPs g.-133A > G and g.-18C > A were
significantly associated with LDL-C response to treatment with
ezetimibe in Caucasians (data not shown). This association was
more significant than any of the corresponding 3-SNP
haplotypes containing the A-A haplotype (P < 0.001),
suggesting that the extent of DNA variation in this LD blocknge in sitosterol measured in the same manner as in Caucasians from the EASE
Least-squares means SE
53.10 4.03
48.38 1.06
45.56 0.67
osterol Haplotype Mean SE
P value
0.0203 A-A-G 48.86 1.02
A-C-C 45.34 0.58
A-C-G 46.03 1.58
G-C-C 46.97 0.72
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discovery and genotyping may be needed to more precisely
define the boundaries of the LD block supporting the SNPs, g.-
133A > G, g.-18C > A, and g.1679C > G. An understanding of
the functional consequence of the associated SNPs and 3-SNP
haplotype underlying these observations is necessary. No
significant difference in levels of NPC1L1 mRNA was
observed in liver tissue when stratified by genotype (data not
shown). Future studies will be necessary to define whether
causality results from one of the SNPs in the haplotype or
another SNP in linkage disequilibrium with the SNPs in this
haplotype and the mechanism by which these genetic variants
influence response.
Discussion
We have provided a detailed characterization of DNA
variations in NPC1L1, the target of ezetimibe, and demon-
strated that common variants in this gene are significantly
associated with LDL-C response to treatment with ezetimibe
co-administered with a statin, but not to baseline LDL-C levels.
Over 140 polymorphisms were identified in NPC1L1 in a
resequencing cohort, with 25 previously represented in dbSNP.
We identified 1 common SNP that was associated with a 15%
incremental reduction in LDL-C levels over the common allele
homozygous genotype following 6 weeks of treatment with
ezetimibe added to ongoing statin therapy. The association was
markedly accentuated in the subset of extreme LDL-C
responders to ezetimibe. The primary association (over all
subjects) remained significant after conservative correction for
all SNPs considered in the analysis and after accounting for
age, sex, and baseline LDL-C covariates. Haplotypes com-
posed of this most significant common variant and others in the
LD block supporting that SNP were also found to be
significantly associated with LDL-C response. Furthermore,
we were able to experimentally support the hypothesis that the
effect of NPC1L1 genetic variation is on intestinal transporter
activity in this case by demonstrating an association between
the SNP and 3-SNP haplotype found to be associated with
LDL-C response and sitosterol response. The LDL-C response
associations to the haplotypes were confirmed in an indepen-
dent trial. In addition, a second intriguing observation was
made. SNP g.28650A > G, which maps to the 3V end of
NPC1L1, demonstrated MAF in all three ethnicities of the
resequencing cohort that were dramatically reduced compared
to the corresponding MAF in the EASE cohort. This reduction
was confirmed by re-genotyping the resequencing cohort with
the same assay as that used in the EASE cohort.
The NPC1L1 variability presented here has a modest effect
on absolute percentage change in LDL-C and explains a small
proportion of variability in response to ezetimibe pharmaco-
therapy (¨1–1.5% depending on which SNP or clinical cohort
is evaluated). However, the magnitude of effect with regard to
cardiovascular risk reduction makes the observation potentially
clinically meaningful to the hypercholesterolemic population.
Large population-based studies show that there is a 2–3%
increased risk of heart disease for each 1 mg/dl change in LDL-C levels [17]. Based on such epidemiological data, the
increased response seen in those carriers of the 3-SNP
haplotype would be anticipated to reduce coronary heart
disease (CHD) risk in these individuals. In addition, these
SNPs have a greater clinically meaningful effect on those
individuals at the tails of the response distribution in the EASE
cohort (¨20% absolute improvement in response for those
heterozygous for the minor allele at g.-18C > A). Still, given
the modest size of the effects and the fact that no single SNP
was found to be associated across the two independent clinical
trials (only the 3-SNP haplotype replicated), additional clinical
trial populations will be needed to clarify how these variants
might affect clinical practice and may help reveal special
circumstances under which these associations exist. In this
regard, it will also be of interest to see whether the 3-SNP
haplotype noted in Tables 3 and 5 predicts response to
ezetimibe monotherapy.
Cholesterol response to lipid-lowering therapies is variable.
A recent study demonstrated that a SNP with an allele frequency
of¨5% in the HMG CoA reductase gene associates with a 19%
lesser response to pravastatin [18]. How to integrate this
observation, as well as the current study into medical practice,
however, is not obvious given the large response seen in those
who do not possess the haplotype predicting increased response.
Clearly, the influence of numerous factors, including genetic
and environmental predisposition to disease as well as
variability in pharmacokinetics, contributes to variability in
drug response. Additional studies simultaneously analyzing
multiple genes critical to cholesterol homeostasis and with
previously demonstrated genetic associations, including LDLR
[19], ABCG5/8 [20], PCSK9 [21], and others, may help
develop a clearer picture of genetic predictors and ultimately
make individualization of pharmacotherapy a reality.
Materials and methods
Population samples for resequencing
To identify SNPs in NPC1L1, conserved regulatory regions, the promoter
region, coding regions, and select intronic regions in NPC1L1 were
sequenced from anonymous, reportedly healthy individuals self-identifying
as Caucasian (n = 198), African American (n = 99), or Hispanic (n = 78).
DNA samples were obtained from the Caucasian and African American
Human Variation Panels collected by the Human Genetic Cell Repository of
the National Institute for General Medical Sciences (NIGMS; Coriell Cell
Repository, Camden, NJ) as well as anonymous donors from Schering-Plough
Corp. All samples came from individuals who provided informed consent to
be part of a DNA polymorphism discovery resource. Information on ethnicity
and gender was collected for each individual in order to assemble the
resource, but all identifying information and phenotypic information were
removed from the individual samples so that links to individual donors were
irreversibly broken.
Single-nucleotide polymorphism discovery
The general strategy for SNP discovery is as previously described [22] with
modifications as detailed. PCR primers were designed (Supplementary Table 3)
using the Primer3 software (http://www.genome.wi.mit.edu/cgi-bin/primer/
primer3.cgi) to amplify 400- to 650-bp segments of the NPC1L1 coding
region as well as approximately 2 kb of the 5V promoter and 100 nucleotides
flanking the intron/exon splice junctions.
J.S. Simon et al. / Genomics 86 (2005) 648–656 655Following DNA amplification, PCR amplicons were sequenced in the
forward and reverse directions using an ABI PRISM BigDye terminator v3.1
Cycle Sequencing DNA Sequencing Kit (Applied Biosystems, Foster City, CA)
on an Applied Biosystems 3730XL DNA Analyzer. Chromatograms were
transferred to a Unix workstation (DEC alpha, Compaq Corp.), base calling
was performed with Phred software (version 0.990722.g), sequences were
assembled with Phrap software (version 3.01) and scanned with Polyphred
software (version 3.5) [23], and the results were viewed with Consed software
(version 9.0) (Phred, Phrap, and Consed are available at http://www.genome.
washington.edu; PolyPhred is available at http://droog.mbt.washington.edu).
Analysis parameters were all maintained at the software’s default settings.
SNPs were named according to the nomenclature proposed by den Dunnin and
Antonarakis [24].
EASE Cohort
To study whether variations in NPC1L1 were associated with LDL-C
response to ezetimibe, a study population was derived from the Ezetimibe Add-
on to Statin for Effectiveness (EASE) Trial ([13]). EASE was a community-
based, randomized, double-blind, placebo-controlled study to evaluate the
effects of 6 weeks of ezetimibe (10 mg/day), added to a stable regimen of statin
therapy, on lipid parameters in hypercholesterolemic patients whose LDL-C
levels exceeded the NCEP ATP III guidelines for CHD risk category. At
enrollment, patients taking a stable dose of statin (any dose, any brand) and
following a NCEP Step 1 or similar cholesterol-lowering diet for at least 6
weeks prior to entry into the study were randomized to either the ezetimibe (n =
2020) or placebo (n = 1010) arm. From the ezetimibe group, 1208 patients
provided consent for genomic analysis and were included in this study. From
the placebo group, 445 subjects provided consent for genomic analysis and
were genotyped in this study.
VYVA Cohort
To validate the associations identified between DNA variants in NPC1L1
and LDL-C response to ezetimibe, a second study population was derived from
a Vytorin (ezetimibe + simvastatin) vs. Atorvastatin trial [25]. This was a
community-based, randomized, double-blind, parallel group, 6-week study to
evaluate the efficacy and safety of ezetimibe + simvastatin versus atorvastatin
in patients with hypercholesterolemia. Following a 4-week placebo run-in
period, 1902 men and women, ages 18 to 79, with hypercholesterolemia, not at
their LDL-C goal as defined by NCEP ATP III guidelines, were randomized to
one of the eight treatment groups: ezetimibe + simvastatin at doses of 10 mg +
10 mg, 10 mg + 20 mg, 10 mg + 40 mg, or 10 mg + 80 mg, or atorvastatin
alone at doses of 10, 20, 40, or 80 mg for 6 weeks. Nine hundred fifty-one
patients were randomized to the atorvastatin monotherapy group and 951 to
the ezetimibe + simvastatin group; 1895 patients were treated with double-
blind study medication (947 in the atorvastatin monotherapy group and 948 in
the ezetimibe + simvastatin group). The distribution of baseline demographics
(age, race, sex, baseline height, weight, waist circumference, and body mass
index) was also comparable across treatment groups. From the ezetimibe +
simvastatin group, 556 Caucasian subjects provided consent for genomic
analysis and were included in this study. From the atorvastatin arm, 576
subjects provided consent for genomic analysis and were genotyped in this
study.
SNP selection and genotyping in the EASE cohort
Twenty-one SNPs identified in the resequencing effort were selected for
genotyping in the EASE cohort. The deletion variant identified in the
resequencing cohort was not considered further. TaqMan Allelic Discrimina-
tion assays were performed using Primer Express software and the Assay-by-
Design service offered by Applied Biosystems (Foster City, CA). All probe/
primer sets were designed to function using universal reaction and cycling
conditions (Supplementary Table 3). After PCR amplification, an endpoint
plate read using Applied Biosystems 7900 HT Sequence Detection System
(SDS) was performed. Genotypes with quality scores below 95% were
repeated.Plasma phytosterol measurement
Phytosterol analyses were performed by SFBC Taylor Technologies
(Princeton, NJ). h-Sitosterol and a d6-Sitosterol internal standard were
extracted from 0.250 ml of EDTA human plasma into hexane using a liquid/
liquid extraction (LLE) procedure. The analytes underwent derivatization by
reaction with N-methyl-N-(trimethylsilyl) trifluoroacetamide, clean-up with a
LLE procedure, and reconstitution in dodecane. The derivatized analytes were
separated by gas chromatography using a DB1701 fused-silica capillary
column and detected by mass spectrometry using positive-ion chemical
ionization. A linear function was fitted to the calibration data using a 1/
(concentration)2 weighted least-squares regression procedure.
Genetic association testing and other statistical analyses
Genetic association analysis was carried out in the EASE cohort with LDL-
C response to ezetimibe treatment considered as the primary outcome variable.
Individual SNPs, haplotypes, and haplotype combinations were the principal
explanatory variables used in the analyses. General linear models were used to
estimate the effects of genotypes, haplotypes, and diplotypes on the LDL-C
response phenotype. Baseline LDL-C levels, sex, age, and race were
investigated to determine whether they gave rise to significant effects. Baseline
LDL-C levels were associated with significant effects in all models and were
therefore included in all analyses. However, the effects of the SNPs on the
percentage change from baseline remained the same regardless of including
baseline value in the model. Since there was no association between any of the
tagging SNPs and baseline LDL-C levels, we report the P values for models
including only the SNPs as predictor variables. When combining both the
EASE and the VYVA cohorts, the variation in response explained by baseline
LDL-C levels is taken into account.
Linear models of the percentage change from baseline LDL-C were
implemented in SAS PROC GLM (Table 2, first two columns), with the SNP as
the predictor with three categories. These were testing our primary hypotheses.
The numbers of copies of the haplotypes (estimated in SAS PROC
HAPLOTYPES) were modeled as categorical variables, again in SAS PROC
GLM (Table 3). In addition, all pairs of haplotype categories were considered
(10 degrees of freedom), also in SAS PROC GLM. Categorical tests, looking at
the distribution of all pairs of haplotypes across the two groups of either low
response or high response were studied.
Hardy-Weinberg equilibrium was assessed on all individual variants using a
standard contingency table comparing observed and predicted genotype
frequencies, where predicted frequencies were estimated by the exact test
procedure implemented in the Haploview software package [11]. Pairwise
linkage disequilibrium values for Supplementary Fig. 1a for all SNP pairs were
computed using the Haploview program. For Supplementary Fig. 1b,
Lewontin’s disequilibrium coefficient DV was computed for all SNP pairs
using the observed allele frequencies for each SNP. Haplotypes were inferred in
the resequencing cohort using a Bayesian approach to haplotype reconstruction
implemented in the PHASE v2.0 software package [9]. SNPs with minor allele
frequencies (MAF) >4% were used in the haplotype reconstruction process.
Recombination hotspot intensity was computed using the Phase v2.0 software
package [25], as previously described [12]. Using a slight variation of the
method presented by Crawford et al. [26] to group haplotypes and SNPs
according to allelic similarity, the eight most common haplotypes identified
over each of the ethnic groups were identified. Haplotypes for all chromosomes
observed were then clustered by similarity using an agglomerative hierarchical
clustering procedure. Similarly, SNPs were clustered by allelic similarity using
the same type of clustering procedure (Supplementary Fig. 2). Tagging SNPs
that distinguish among the common haplotypes (frequency >2%) were then
identified visually from the resulting color matrix plot in Supplementary Fig. 2.
Haplotypes for Tables 3 and 4 were inferred using the statistical software
package SAS, in the EASE cohort.
To determine whether minor allele frequencies for each SNP were
equivalent for all ethnic groups, the Pearson’s m2 statistic was computed based
on the expected number of minor alleles for each ethnic group, estimated by
multiplying the number of individuals in an ethnic group by the fraction of
minor alleles observed over all of the individuals in the cohort. Under the null
hypothesis that the frequencies are the same across all ethnic groups, the
J.S. Simon et al. / Genomics 86 (2005) 648–656656Pearson’s m2 statistic has an asymptotic m2 distribution with degrees of freedom
equal to the number of ethnic groups minus 1. In cases where the MAF for a
given SNP in any of the ethnic groups was too small for the asymptotics to
hold, permutation testing was performed, if possible, to estimate significances
empirically. In such cases, the permutation step consisted of randomly
assigning individuals in a given cohort to genotypes for the SNP of interest,
preserving the overall allele counts observed in the cohort, and then computing
the Pearson’s m2 statistic.
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